Pulmatrix says objectives from Phase 1/1b study of Pulmazole 'successfully met'
Pulmatrix, which previously reported positive top line data from Parts 1 and 2 of the first-in-human study of Pulmazole in normal healthy volunteers and from Part 3 in asthmatic subjects, announced that final results "both extend and confirm the previously reported positive top line data." Pulmatrix plans to initiate a Phase 2 trial in asthmatic patients with ABPA patients in Q4 2018. Jim Roach, Chief Medical Officer of Pulmatrix, said, "With the phase 1 study results now firmly in hand, we remain very enthusiastic about the potential for Pulmazole to address the significant limitations associated with oral itraconazole, and more importantly, to address the significant unmet medical need that patients with asthma and ABPA currently face. We believe that these results strongly support the further advancement of Pulmazole into Phase 2 and look forward to getting our next study underway next month."